Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico
Dengvaxia is the first dengue vaccine recommended in the United States (U.S.). It is recommended for children aged 9–16 y with laboratory-confirmed previous dengue infection and living in areas where dengue is endemic. We conducted focus groups with parents and in-depth interviews with key informant...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2323264 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717402834567168 |
|---|---|
| author | Coral Rosado-Santiago Carmen L. Pérez-Guerra Nicole M. Vélez-Agosto Claudia Colón-Burgos Karla M. Marrero-Santos Susanna K. Partridge Amy E. Lockwood Cathy Young Steve H. Waterman Gabriela Paz-Bailey Iris Cardona-Gerena Angel Rivera Laura E. Adams Joshua M. Wong |
| author_facet | Coral Rosado-Santiago Carmen L. Pérez-Guerra Nicole M. Vélez-Agosto Claudia Colón-Burgos Karla M. Marrero-Santos Susanna K. Partridge Amy E. Lockwood Cathy Young Steve H. Waterman Gabriela Paz-Bailey Iris Cardona-Gerena Angel Rivera Laura E. Adams Joshua M. Wong |
| author_sort | Coral Rosado-Santiago |
| collection | DOAJ |
| description | Dengvaxia is the first dengue vaccine recommended in the United States (U.S.). It is recommended for children aged 9–16 y with laboratory-confirmed previous dengue infection and living in areas where dengue is endemic. We conducted focus groups with parents and in-depth interviews with key informants (i.e. practicing pediatricians, physicians from immunization clinics, university researchers, and school officials) in Puerto Rico (P.R.) to examine acceptability, barriers, and motivators to vaccinate with Dengvaxia. We also carried out informal meetings and semi-structured interviews to evaluate key messages and educational materials with pediatricians and parents. Barriers to vaccination included lack of information, distrust toward new vaccines, vaccine side effects and risks, and high cost of/lack of insurance coverage for laboratory tests and vaccines. Motivators included clear information about the vaccine, a desire to prevent future dengue infections, the experience of a previous dengue infection or awareness of dengue fatality, vaccine and laboratory tests covered by health insurance, availability of rapid test results and vaccine appointments. School officials and parents agreed parents would pay a deductible of $5–20 for Dengvaxia. For vaccine information dissemination, parents preferred an educational campaign through traditional media and social media, and one-on-one counseling of parents by healthcare providers. Education about this vaccine to healthcare providers will help them answer parents’ questions. Dengvaxia acceptability in P.R. will increase by addressing motivators and barriers to vaccination and by disseminating vaccine information in plain language through spokespersons from health institutions in P.R. |
| format | Article |
| id | doaj-art-3c45a2310ad94de6926a29eabce01de4 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-3c45a2310ad94de6926a29eabce01de42025-08-20T03:12:40ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2323264Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto RicoCoral Rosado-Santiago0Carmen L. Pérez-Guerra1Nicole M. Vélez-Agosto2Claudia Colón-Burgos3Karla M. Marrero-Santos4Susanna K. Partridge5Amy E. Lockwood6Cathy Young7Steve H. Waterman8Gabriela Paz-Bailey9Iris Cardona-Gerena10Angel Rivera11Laura E. Adams12Joshua M. Wong13Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USADepartment of Clinical Psychology, The University of Texas Rio Grande Valley, Edinburg, TX, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USANational Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USANational Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USAPuerto Rico Department of Health, San Juan, PR, USAPuerto Rico Department of Health, San Juan, PR, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USADivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR, USADengvaxia is the first dengue vaccine recommended in the United States (U.S.). It is recommended for children aged 9–16 y with laboratory-confirmed previous dengue infection and living in areas where dengue is endemic. We conducted focus groups with parents and in-depth interviews with key informants (i.e. practicing pediatricians, physicians from immunization clinics, university researchers, and school officials) in Puerto Rico (P.R.) to examine acceptability, barriers, and motivators to vaccinate with Dengvaxia. We also carried out informal meetings and semi-structured interviews to evaluate key messages and educational materials with pediatricians and parents. Barriers to vaccination included lack of information, distrust toward new vaccines, vaccine side effects and risks, and high cost of/lack of insurance coverage for laboratory tests and vaccines. Motivators included clear information about the vaccine, a desire to prevent future dengue infections, the experience of a previous dengue infection or awareness of dengue fatality, vaccine and laboratory tests covered by health insurance, availability of rapid test results and vaccine appointments. School officials and parents agreed parents would pay a deductible of $5–20 for Dengvaxia. For vaccine information dissemination, parents preferred an educational campaign through traditional media and social media, and one-on-one counseling of parents by healthcare providers. Education about this vaccine to healthcare providers will help them answer parents’ questions. Dengvaxia acceptability in P.R. will increase by addressing motivators and barriers to vaccination and by disseminating vaccine information in plain language through spokespersons from health institutions in P.R.https://www.tandfonline.com/doi/10.1080/21645515.2024.2323264Dengue vaccineDengvaxiavaccine acceptabilityqualitative methodsPuerto Rico |
| spellingShingle | Coral Rosado-Santiago Carmen L. Pérez-Guerra Nicole M. Vélez-Agosto Claudia Colón-Burgos Karla M. Marrero-Santos Susanna K. Partridge Amy E. Lockwood Cathy Young Steve H. Waterman Gabriela Paz-Bailey Iris Cardona-Gerena Angel Rivera Laura E. Adams Joshua M. Wong Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico Human Vaccines & Immunotherapeutics Dengue vaccine Dengvaxia vaccine acceptability qualitative methods Puerto Rico |
| title | Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico |
| title_full | Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico |
| title_fullStr | Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico |
| title_full_unstemmed | Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico |
| title_short | Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico |
| title_sort | perceptions of dengue risk and acceptability of a dengue vaccine in residents of puerto rico |
| topic | Dengue vaccine Dengvaxia vaccine acceptability qualitative methods Puerto Rico |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2323264 |
| work_keys_str_mv | AT coralrosadosantiago perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT carmenlperezguerra perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT nicolemvelezagosto perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT claudiacolonburgos perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT karlammarrerosantos perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT susannakpartridge perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT amyelockwood perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT cathyyoung perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT stevehwaterman perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT gabrielapazbailey perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT iriscardonagerena perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT angelrivera perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT lauraeadams perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico AT joshuamwong perceptionsofdengueriskandacceptabilityofadenguevaccineinresidentsofpuertorico |